Taken together, these studies demonstrated a broad role for MED1 in mediating endocrine resistance of human breast cancer cells, and support its potential usage as a possible therapeutic target to overcome endocrine resistance, alone or in combination with current endocrine therapy regiments. This evidence concerns the gene MED1 and breast cancer.